Determination of Pre/Post Treatment Changes in Prostate Specific Antigen Levels in Patients with Acute Prostatitis

Abstract

Introduction: Given that studies on the association between pre/post-treatment PSA levels in acute prostatitis are limited and investigations in men from different communities are few, the present study aimed to determine the pre/post-treatment changes in the prostate-specific antigen (PSA) levels in patients with acute prostatitis. Method: The current cross-sectional study was conducted in 2020 on a population of men with acute prostatitis. The patients were then referred to a laboratory to measure PSA levels for a definitive diagnosis of acute prostatitis. Prostate volume was determined using ultrasound. Afterward, drug treatment was started for the patient, followed by monitoring. The PSA levels were re-measured, and prostate volume was recorded after treatment. Patient information included patient profile, age, date of the first visit, PSA level at the baseline (before treatment), diagnosis of acute prostatitis, time to start treatment, time to end treatment, PSA level after treatment, and prostate volume. Results: The mean and standard deviation of the age of these patients was 59.90±6.31 years old. The results showed a significant relationship between age and primary PSA at the beginning of diagnosis and PSA reduction. (P-value<0.05). There is a significant relationship between age and duration of treatment (P-value=0.001). The duration of treatment was significantly related to the reduction of PSA, the amount of primary PSA at the beginning of diagnosis, and the amount of secondary PSA after treatment (P-value<0.05). Conclusion: The study's findings can be concluded that the duration of treatment can effectively reduce the level of PSA in patients with acute prostatitis. Extensive studies with a control group for future studies are recommended.

Keywords

• treatment
• prostate-specific antigen
• acute prostatitis